Ming‐Ju Wu

机构：National Chung Hsing University, China Medical University, Taichung Veterans General Hospital, Taipei Medical University, Chung Shan Medical University · ORCID：0000-0002-8585-4392

发表论文 227 篇 · 总被引 3760 次 · h-index 30

代表论文

• Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (2023 · The Lancet · 被引 301)
• Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023 · The Lancet · 被引 226)
• Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis (2022 · Diabetes Care · 被引 215)
• Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (2023 · Annals of Internal Medicine · 被引 102)
• Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial (2024 · Clinical Journal of the American Society of Nephrology · 被引 72)
• Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan (2023 · JAMA Network Open · 被引 35)